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Abstract
Background: The present study investigates the effects of ginsenosides Rh1 and Rg2 against 6-hydroxydopamine
(6-OHDA), a neurotoxin on SH-SY5Y cells and PC-12 cells. The effects of these two ginsenosides on neuronal
differentiation are also examined.
Methods: LDH assay was used to measure cell viability after exposure to 6-OHDA and ginsenosides. Neuronal
differentiation was evaluated by changes in cell morphology and density of neurite outgrowths. Western blotting
was used to determine the ginsenosides’ effects on activation of extracellular signal-regulated protein kinases (ERKs).
Results: Rh1 and Rg2 attenuated 6-OHDA toxicity in SH-SY5Y cells and induced neurite outgrowths in PC-12 cells.
6-OHDA-induced ERK phosphorylation was decreased by Rh1 and Rg2. 20(R)-form and 20(S)-form of the
ginsenosides exerted similar effects in inducing neurite outgrowths in PC-12 cells.
Conclusion: The present study demonstrates neuroprotective effects of ginsenosides Rh1 and Rg2 on neuronal cell
lines. These results suggest potential Chinese medicine treatment for neurodegenerative disorders (eg Parkinson’s
disease).
Background
Parkinson’s disease (PD) is a common motor system disor-
der characterized clinically by rigidity, resting tremor and
slow movements [1]. It is associated with a progressive
loss of dopaminergic neurons within the substantia nigra
and depletion of dopamine in the striatal region [2,3].
Dopamine (DA) is a catecholamine neurotransmitter in
the brain, produced mainly in the substantia nigra and the
ventral tegmental area. Six-hydroxydopamine (6-OHDA)
is a hydroxylated analogue of DA. Metabolism of dopa-
mine leads to the generation 6-OHDA [4,5] which exerts
specific neurotoxicity on catecholaminergic neurons by a
selective transport mechanism, including its uptake and
accumulation in those neurons [6] due to its structural
similarity with DA. Recent studies demonstrated that
6-OHDA toxicity might involve an extracellular autoxida-
tion process [6,7]. Alterations in intracellular signaling
pathways including the MAPKs pathway were recently
found to accompany 6-OHDA toxicity. Specifically, extra-
cellular signal-regulated protein kinases (ERK) activation
and c-jun N-terminal kinase (JNK) activation have been
observed in various models [8-10].
Ginseng, the fleshy root of the Panax species in the
family Araliaceae, is an herbal medicine traditionally
used in East Asia and is now popular worldwide. Recent
Studies have demonstrated its beneficial effects in vivo
and in vitro in various pathological conditions such as
cardiovascular diseases, immunodeficiency, cancer and
hepatotoxicity [11]. Moreover, increasing evidence sug-
gests that ginsenosides are responsible for the pharma-
cological effects of ginseng [12]. As ginsenosides (or
ginseng saponins) possess antioxidant, anti-apoptotic,
anti-inflammatory and immunostimulant properties;
they can positively affect neurodegenerative diseases or
delay neuronal aging [11]. In fact, ginsenosides have
been reported to have various actions on the central
nervous system (CNS) [13,14], in particular, their anti-
Parkinson effects. Ginsenosides Rb1 and Rg1 protect
dopaminergic neurons in vivo and in vitro against toxi-
city induced by MPTP, 6-OHDA or glutamate [15-20].
They also enhance neurite outgrowth with or without
stimulation of the nerve growth factor (NGF) [14,18,21].
Ginsenosides are classified into two major groups,
namely dammarane and oleanane types [22]. Most
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ginsenosides belong to the dammarane type which is
further divided into the protopanaxadiol (PPD) group
and the protopanaxatriol (PPT) group according to their
genuine aglycones [23]. Both ginsenosides Rh1 and Rg2
belong to the PPT group. While ginsenosides in the
PPT group have generally stimulating effects on the
CNS, such as anti-fatigue and hypertensive effects, ana-
bolic stimulation, enhanced mental acuity and intellec-
tual performance, ginsenosides in the PPD group are
generally CNS-depressants with anti-stress, antipyretic
and hypotensive effects [24]. However, the action
mechanism of ginsenosides, Rh1 and Rg2 in particular, is
still unclear. Each ginsenoside has 20(R) and 20(S) forms.
However, the C-20 stereocytochemistry is relevant to the
effects of ginsenosides still await investigation.
Nuclear receptors are transcriptional factors that spe-
cifically regulate target gene expression in response to
hormones and other metabolic ligands [25]. Estrogen
receptors (ERs), thyroid hormone receptor (TR), gluco-
corticoid receptors (GRs) are well-known subfamilies of
nuclear receptors. The two ER subtypes, namely ERa
and ERb, together with their splice variants mediate
diverse physiological processes in different tissues
[26,27] while ERa seems to be the major component in
mediating neuroprotection and estrogen-induced differ-
entiating effects [28,29]. Previous studies revealed that
liganded ERa enhanced NGF-induced differentiation in
PC-12 cells while in the absence of 17b-estradiol
(17bE2), the expression of ERa actually partly sup-
pressed NGF-induced neurite outgrowth or expression
of neuronal markers [30]. Increased NGF-induced gene
expression by 17bE2 suggests the transcriptional activity
of ERa on PC-12 cell differentiation. By contrast, several
studies demonstrated that ERa was involved in the med-
iation of neuronal survival against various insulted
including glutathione depletion, serum deprivation and
glutamate toxicity [29,31,32].
Mitogen-activated protein kinases (MAPKs) are an
evolutionarily conserved family of serine/threonine-spe-
cific kinases that regulate various cellular activities, such
as cell proliferation, differentiation and apoptosis
[33,34]. In mammals, MAPKs include the ERKs, p38
MAPK and c-Jun NH2-terminal kinases (JNKs) [35].
ERK’s role in neurotoxicity is dependent on the experi-
mental paradigm. Previous studies suggested that the
activation of ERK by growth factors or by stress con-
ferred a survival advantage to cells [36,37]; however,
recent studies found that ERK promoted neuronal cell
death in vivo and in vitro [38,39] while inhibition of
ERK had protective effects in various models of neuro-
nal cell death [40-42].
The present study aims to evaluate the effects of gin-
senosides Rh1 and Rg2 on neuroprotection, cell differen-
tiation and on ERK activation in neuronal cells.
Methods
Chemicals
Ginsenosides Rh1 and Rg2 (enantiomeric mixtures) as
well as individual stereoisomers, ie 20(R)-Rh1, 20(S)-Rh1,
20(R)-Rg2 and 20(S)-Rg2 in powder form (>99% purity)
were provided by ZHJ (Figure 1). The powder was dis-
solved in dimethyl sulfoxide (DMSO) to a stock solution
of 10 mM. Further dilution was made in complete cul-
ture medium or serum-free medium, depending on the
experimental setup.
Nerve Growth Factor-b (NGF-b) from rat (Sigma-
Aldrich; USA) was reconstituted using sterile PBS con-
taining 0.1% BSA to a stock concentration of 1 μg/ml.
Further dilution was made in complete culture medium
or serum-free medium, depending on the experimental
setup.
Six-hydroxydopamine (6-OHDA) hydrochloride
(Sigma) was dissolved in sterile Hank’s Buffered Salt
Solution (HBSS) containing 0.1% ascorbic acid to a
1 mM stock solution, and further dilution to target con-
centrations was made in serum-free medium.
Cell culture
SH-SY5Y cells were cultured in Dulbecco’s modified eagle
medium containing nutrient mixture F-12 (DMEM/F12)
(Gibco; USA) with 10% Fetal Bovine Serum (FBS) (Gibco;
USA) and 0.5% Penicillin-Streptomycin-Neomycin (PSN)
Antibiotic Mixture (Gibco; USA). The cells were incubated
in a humidified incubator at 37°C, 5% CO2. The culture
medium was renewed every three to four days and the
cells were subcultured every seven to eight days. The cells
were detached from the culture flask by treatment with
trypsin-EDTA (Gibco; USA) at a ratio of 1 ml per 25 cm2
for half a minute.
PC-12 cells were cultured in F-12 K Medium (Gibco;
USA) with 15% Horse Serum (HS) (Gibco; USA), 2.5%
FBS (Gibco; USA) and 1% PSN Antibiotic Mixture
Figure 1 Chemical structure of ginsenosides Rg2 and Rh1.
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(Gibco). The cells were seeded on Type-I rat-tail col-
lagen (Millipore; USA) coated culture flasks (Nunclon;
USA), 6-well plastic plates (Iwaki; Japan) and 4-well
plastic plates (Nunclon; USA). The cells were incubated
in a humidified incubator at 37°C, 5% CO2. The culture
medium was renewed every three to four days and the
cells were subcultured every seven to eight days. The
cells were detached by physical flushing.
Neurite outgrowth assessments
PC-12 cells were seeded in 4-well plates at a density of
30,000 cells per well in complete culture medium. The
medium was changed after 24 hours to complete the
culture medium plus 20 μM ginsenoside Rh1 or Rg2
with or without 5 ng/ml NGF co-treatment. The con-
centration of NGF was chosen based on previous obser-
vations that 5 to 10 ng/ml NGF-b in serum-free
medium induced optimal neurite outgrowth in PC-12
cells [26]. After 48 hours, the cells were observed under
an inverted light microscope (ZEISS; Germary) at 200 ×
magnification and photos were taken for subsequent
quantification of neurite outgrowth.
The cells were classified according to their morphol-
ogy into three groups [43], namely (1) cells with long
neuritis (ie cells with at least one neurite twice the
length of its cell body diameter); (2) cells with short
neuritis (ie cells without a long neurite but with at least
one neurite that was longer than its cell body diameter);
(3) cells without neuritis (ie cells without any neurite
outgrowth that was longer than its cell body diameter.
At least 120 cells were counted for each treatment. The
percentages of each group of cells in each treatment
were determined.
Analysis of cytotoxicity
Cytotoxicity after 6-OHDA and/or ginsenosides expo-
sure was quantitatively measured by LDH cytotoxicity
assay with Cytotoxicity Detection Kit (Roche Applied
Science; Germary). The cells were seeded in 96-well
plates at a density of 30,000 cells per well. For 6-OHDA
and ginsenosides toxicity assay, 24 hours after seeding,
the cells were washed once with serum-free medium,
and then treated with different concentrations of 6-
OHDA (5, 10, 20, 50 and 100 μM) or ginsenosides (10
and 20 μM of Rh1 or Rg2) for another 24 hours. Low
control (serum-free medium) and high control (serum-
free medium containing 2% Triton X-100) groups were
set up to represent normal cell death and maximum cell
death respectively. For the assay for ginsenosides’ effects
on 6-OHDA toxicity, 24 hours after seeding, the cells
were pre-incubated in serum-free medium containing
ginsenosides (10 and 20 μM of Rh1 or Rg2) for 24
hours. Then the cells were challenged with 6-OHDA
(40 or 60 μM) with or without ginsenosides co-treat-
ment for another 24 hours.
Prior to LDH assay, the 96-well plates were centri-
fuged (Beckman Allegra 6R; Beckman Instruments,
USA) at 1000 g for 10 minutes to sediment the cells.
Then 46 μl of supernatant was drawn from each well to
a new empty well. The dye solution was mixed with the
catalyst solution at a volume ratio of 45:1 and immedi-
ately after, 46 μl of reaction mixture was added to each
well. The plate was incubated in the dark for 30 min-
utes, and then the optical density of the reaction mix-
ture was measured with a multi-functional plate reader
(Tecan Infinit F200; TECAN; Switzerland) at 495 nm
with reference at 690 nm. The readings were normalized
by subtracting the optical density of corresponding med-
ium. The percentage of cell death (cytotoxicity) was cal-
culated according to the following formula:
Cytotoxicity (%) =
[
(exp. value− low control) / (high control − low control)]×100
Western blot analysis of ERK1/2 activation
The cells were seeded in 6-well plates at a density of
1,000,000 cells per well in complete culture medium.
For SH-SY5Y cells, treatment was applied 24 hours after
seeding whereas for PC-12 cells, 24 hours after seeding
the medium was changed to complete medium supple-
mented with 5 ng/ml NGF for 48 hours to induce differ-
entiation. Treatment was done with serum-free medium
for both cells. The cells were exposed to 20 μM ginse-
noside for 24 hours and then 20 μM ginsenoside plus
50 μM 6-OHDA for 3 hours. The cells were washed by
ice-cold PBS before lysed with lysis buffer containing
Protein Extraction Reagent (Novagen; USA) and Pro-
tease Inhibitor Cocktail Set III (Calbiochem; USA)
(200:1). The cell lysate was collected and centrifuged
(5430R; Eppendorf; Germany) (14,000g,) at 4°C for 30
minutes. The supernatant containing the proteins was
collected for protein quantification or storage at -80°C.
The protein concentration in the lysate was determined
with a commercially available kit (Bio-Rad; USA) and cal-
culated from a standard protein concentration curve.
Protein samples were adjusted to equal concentration
and volume by lysis buffer and then mixed with equal
volume of sampler buffer (Bio-Rad; USA) containing 5%
b-mercaptoethanol by volume. The protein samples were
heated at 100°C for five minutes before electrophoresis.
The proteins were separated on SDS-polyacrylamide gel
(4.5% stacking gel, 10% lower gel) and then transferred to
Polyvinylidene Fluoride (PVDF) Membrane (Bio-Rad;
USA) overnight. The membrane was blocked with 5%
non-fat dry milk in Tris buffered saline-Tween (TBST)
solution. The membrane was then incubated with Phos-
pho-p44/42 MAPK (Erk1/2) or p44/42 MAPK (Erk1/2)
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antibody for two hours followed by horseradish peroxi-
dase (HRP)-conjugated secondary antibody for one hour.
Bands on the PVDF membranes were visualized by a
commercially available enhanced luminal-based chemilu-
minescent substrate (WESTSAVE UpTM; AbFrontier;
Korea) and developed on films (Agfa; Germary). The
integrated optical density (IOD) of bands was measured
with Metamorph software (Universal Imaging Corpora-
tion; USA).
Statistical analysis
All data were presented as mean ± standard deviation
(SD) unless otherwise indicated. Statistical differences
between the treatment and control groups were ana-
lyzed by Welch’s t-test with SigmaPlot 11.0 software
(Systat Software, Inc.; Canada). For comparison between
multiple groups, one way analysis of variance (ANOVA)
was used followed by a Dunnett’s post-hoc test. P < 0.05
was considered statistically significant.
Results
6-OHDA and ginsenosides cytotoxicity
Cytotoxicity of 6-OHDA and ginsenosides Rh1 and Rg2
on SH-SY5Y cells was tested with the LDH assay. A sig-
nificant increase (P = 0.010) in LDH release was observed
following 24 hours of incubation with 6-OHDA at con-
centrations higher than 20 μM (Figure 2a), indicating
that 6-OHDA exerted toxicity on SH-SY5Y cells. It may
be suggested that the percentage of cell death increased
in a dose-dependent manner within the range of 5 μM to
100 μM 6-OHDA. 50% cell death was estimated to occur
at approximately 60 μM 6-OHDA (LC-50). Based on this
experiment, two concentrations (40 μM and 60 μM)
around and lower than the LC-50 were chosen for later
experiments examining the effects of ginsenoside
pretreatment on 6-OHDA toxicity.
No significant difference in LDH release was observed
following 24 hours of incubation with the two ginseno-
sides (10 μM and 20 μM) comparing with the control
group (Figure 2b). These two concentrations were used
for subsequent experiments examining the effects of
ginsenoside pretreatment on 6-OHDA toxicity.
Effects of ginsenoside pretreatment on 6-OHDA toxicity
A decrease in mean cytotoxicity was observed for ginseno-
side-pretreated groups upon exposure to both 40 and
60 μM 6-OHDA. Statistical analysis showed that upon
40 μM 6-OHDA exposure, the mean toxicity for ginseno-
side-pretreated groups were not significantly different (P =
0.184, One Way ANOVA) from that of the un-pretreated
group (Figure 2c). However, upon 60 μM 6-OHDA expo-
sure, the mean toxicity for three ginsenoside-pretreated
groups (10 μM Rh1: 13.02 ± 4.26%; 10 μM Rg2: 11.86 ±
1.95%; 20 μM Rg2: 12.12 ± 5.57%) were found to be
significantly different (P = 0.022 for 10 μM Rh1 and P =
0.036 for 20 μM Rg2; P = 0.002 for 10 μM Rg2) from that
of the un-pretreated group (22.55 ± 1.61%; Figure 2d).
These results suggest neuroprotective effects of ginseno-
sides Rh1 and Rg2 against 6-OHDA toxicity on SH-SY5Y
cells.
Neurite outgrowth assessment and morphological
observation
The morphology of PC-12 cells was examined under
inverted light microscope 48 hours after treatment. In their
native states the PC-12 cells appear polygonal in shape and
very few cells possess neurites while upon 5 ng/ml NGF
exposure the cells extend obvious neurite outgrowths. Rh1
and Rg2 treatments both enhanced neurite outgrowths in
the absence of NGF while their effects were potentiated
with NGF co-treatment (Figure 3a). The morphological
changes of PC12 cells were then quantified. After treat-
ment with ginsenosides Rh1 and Rg2, the percentage of
PC12 cells possessing neurites was more than that of con-
trol. (Figure 3b).
Inhibition of 6-OHDA-induced ERK1/2 phosphorylation by
ginsenosides
50 μM 6-OHDA induced ERK1/2 phosphorylation in both
SH-SY5Y cells and PC-12 cells after three hours of incuba-
tion while without 6-OHDA the phosphorylation of ERK1/
2 was barely detectable. Pretreatment with ginsenosides
Rh1 (Figure 4) or Rg2 (Figure 5) for 24 hours reduced the
levels of ERK1/2 phosphorylation in both cells. Statistical
analysis (Welch’s t-test) showed that the means of IOD-
pERK /IODERK relative to the 6-OHDA control group were
significantly reduced (SH-SY5Y :P < 0.001 for Rh1 and P =
0.015 for Rg2; PC-12: P = 0.027 for Rh1 and P < 0.001 for
Rg2) with ginsenoside pretreatment (Figures 4 and 5).
These results suggest a protective role of ginsenosides Rh1
and Rg2 on both cells against 6-OHDA toxicity.
Ginsenoside stereoisomers induce neurite outgrowth
Neurite outgrowth assessment in PC12 cells was
repeated with the individual stereoisomers of ginseno-
sides, ie 20(R)-Rh1, 20(S)-Rh1, 20(R)-Rg2 and 20(S)-Rg2.
The percentage of cells possessing neuritis with the
treatments of all four ginsenoside stereoisomers was found
to be higher than that of control. And these treatments
increased the neurite outgrowth in the absence of NGF
while their effects potentiated with NGF co-treatments
(Figure 6).
Discussion
The present study demonstrates that 6-OHDA is cyto-
toxic to SH-SY5Y cells, and the toxicity increases in a
dose-dependent manner. Pretreatment with ginsenosides
Rh1 or Rg2 attenuates the 6-OHDA toxicity while not
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being toxic to the cells themselves. The results suggests
that Rh1 and Rg2 may have induced changes in cellular
activity, which helped the cells overcome 6-OHDA toxi-
city. It is well documented that oxidative stress is impli-
cated in 6-OHDA-induced neuronal cell death [6,17].
The pathophysiology of many neurodegenerative disor-
ders, including Alzheimer’s disease and PD are also
closely associated with oxidative damage [44]. Neuro-
protection can therefore be partly achieved by counter-
action of the oxidative stress with various anti-oxidants,
such as glutathione, flavonoids, estrogens and phytoes-
trogens [44-46]. Ginsenosides have been widely reported
to have anti-oxidation activities [15-17] and to promote
neurite outgrowth [14,18]. A study by Liu et al. on the
structure-activity relationship predicts that Rh1 is an
anti-oxidant while Rg2 is a pro-oxidant [47]; however,
Rg2 has been reported in other studies to have exhibited
an anti-oxidation effect [46,48]. To further elucidate the
mechanisms of Rh1 and Rg2, we will investigate whether
anti-oxidative activity plays a role here.
Figure 2 Figures showing the effect of ginsenoside treatments on SH-SY5Y cells against 6-OHDA toxicity a. Six-hydroxydopamine toxicity
on SH-SY5Y cells. The percentage of cell death (cytotoxicity) after 24 hours of exposure to different concentrations of 6-OHDA. Values are
presented as mean ± SD (n = 3). (Welch’s t-test, ** P = 0.010, ***P < 0.001, vs. control). Negative percentage is considered to be zero percentage
as it is resulted by calculation of the LDH assay formula. b. Ginsenosides toxicity on SH-SY5Y cells. The percentage of cell death (cytotoxicity)
after 24 hours of exposure to different concentrations of ginsenosides Rh1 and Rg2 Values are presented as mean ± SD (n = 3). The cytotoxicity
of ginsenoside-treated groups and the control group was not significantly different (one way ANOVA, P = 0.110). c. Effect of ginsenoside
pretreatment on 40 μM 6-OHDA toxicity on SH-SY5Y cells. The percentage of cell death (cytotoxicity) after 24 hours of pretreatment of
ginsenosides Rh1 and Rg2 (10 μM and 20 μM) followed by 24 hours co-treatment with ginsenosides together with 40 μM 6-OHDA. Values are
presented as mean ± SD (n = 3). The cytotoxicity of ginsenoside-pretreated groups were not significantly different from that of the un-
pretreated group (one way ANOVA, P = 0.184). d. Effect of ginsenoside pretreatment on 60 μM 6-OHDA toxicity on SH-SY5Y cells. The
percentage of cell death (cytotoxicity) after 24 hours of pretreatment of ginsenosides Rh1 and Rg2 (10 μM and 20 μM) followed by 24 hours co-
treatment with ginsenosides together with 60 μM 6-OHDA. Values are presented as mean ± SD (n = 3). (Welch’s t-test, *P < 0.05, ** P < 0.01, vs.
un-pretreated group. 10 μM Rh1: P = 0.022; 10 μM Rg2: P = 0.002; 20 μM Rg2: P = 0.036).
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Figure 3 Comparison of morphology and quantitative changes in PC-12 cells a. Morphology comparison of PC-12 cells with or without
ginsenoside and/or NGF treatment. (A) Control; (B) 5 ng/ml NGF; (C) 20 μM Rh1; (D) 20 μM Rh1 + 5 ng/ml NGF; (E) 20 μM Rg2; (F) 20 μM Rg2 +
5 ng/ml NGF. Scale Bar: 50 mb. Quantitative changes in PC-12 cell morphology. The stacked bars illustrate the percentages of cells that do not
possess neurites, possess short neurites only, or possess long neurites in each treatment group. At least 120 cells were counted for each
treatment. Ginsenosides Rh1 and Rg2 (20 μM) both increased the percentage of cells possessing short or long neurites in the absence of NGF
(Rh1: 20.3%, 6.5%; Rg2: 25.1%, 7.3%) compared to the control group (8.5%, 2.6%). In the presence of NGF (5 ng/ml) the effects of Rh1 and Rg2
were mostly enhanced, but were not greatly different from NGF treatment alone (Rh1+NGF: 26.8%, 10.8%; Rg2+NGF: 22.9%, 10.9%; NGF: 22.7%,
11.3%).
Figure 4 Inhibition of ERK1/2 phosphorylation by ginsenosides
Rh1 and Rg2 in SH-SY5Y cells. (A) Representative immunoblots
showing the reduction in ERK1/2 phosphorylation by ginsenosides
pretreatment in SH-SY5Y cells. (B) Bar chart showing reduction in
IODpERK/IODERK of ginsenosides pretreated groups relative to the 6-
OHDA control group (data presented as mean ± SD, n = 3).
(Welch’s t-test, * P = 0.015, *** P < 0.001).
Figure 5 Inhibition of ERK1/2 phosphorylation by ginsenosides
Rh1 and Rg2 in PC-12 cells. (A) Representative immunoblots
showing the reduction in ERK1/2 phosphorylation by ginsenosides
pretreatment in PC-12 cells. (B) Bar chart showing reduction in IOD
pERK/IODERK of ginsenosides pretreated groups relative to the 6-
OHDA control group (data presented as mean ± SD, n = 3).
(Welch’s t-test, * P = 0.027, *** P < 0.001).
Li et al. Chinese Medicine 2011, 6:19
http://www.cmjournal.org/content/6/1/19
Page 6 of 9
The neuroprotective effects of Rh1 and Rg2 were also
exemplified in MAPK/ERK signaling pathway. 6-OHDA
induced ERK1/2 phosphorylation in SH-SY5Y cells as
well as PC-12 cells, and the phosphorylation could be
partly inhibited by pretreatment with Rh1 and Rg2. It
has been reported that ginsenosides may bind to trans-
membrane membrane receptors to activate related sig-
naling pathways downstream [49]. The MAPK-regulated
kinases have a prominent role in regulating cellular pro-
cesses such as proliferation, differentiation and adapta-
tion [8]. Activation of two families of MAPKs, JNK/
SAPK and p38 MAPK is often correlated with neurode-
generation while the role of ERKs is less clear and may
vary depending on the specific cell type [45]. In the 6-
OHDA neuronal models, there seems to be a time
course-dependent relationship between ERK phosphory-
lation and its effects. The first peak of phosphorylated
ERK around 15 minutes after 6-OHDA treatment
appears to be pro-survival whereas the second one that
comes after several hours results from sustained mito-
chondrial ERK phosphorylation which enhances neuro-
nal cell death [50,51]. In the present study, significant
ERK1/2 phosphorylation was found 3 hours after the 6-
OHDA treatment, which is likely to be sustained rather
than transient. However, we do not prelude that the
change in ERK1/2 phosphorylation could be a biphasic
response. The reduction of ERK1/2 phosphorylation by
Rh1 or Rg2 pretreatment may indicate their neuropro-
tective effects against 6-OHDA toxicity. Another study
also found similar inhibition effects on ERK1/2 phos-
phorylation exerted by Rg1 [8].
In the present study, wild-type PC-12 cells were used
as a model for neuronal differentiation. The result
showed that ginsenosides Rh1 and Rg2 induced neurite
outgrowth both in the absence and presence of NGF.
However, the dose-response relationship and time-
dependent changes, and whether this effect promotes
neuroprotection remain to be determined. The synergis-
tic effect between NGF and ginsenosides was not appar-
ent, perhaps because the NGF concentration used was
already very potent in inducing PC-12 cell differentia-
tion, or perhaps the incubation time was not long
enough for that to occur. The mechanism of neurite
induction by ginsenosides is still undefined but may be
related to nuclear receptor signaling.
Ginsenosides are steroidal saponins similar to estradiol
in terms of their chemical structure (Figure 1). They have
a rigid four trans-ring steroid skeleton, with a modified
side-chain at C20 whereas estradiol does not possess a
side-chain [52]. This structural similarity may be the cause
for their similar activities as well, for instance, binding to
the steroid hormone receptor ERa. Moreover, ginseno-
sides and estrogens share many of their target tissues. Pre-
vious studies have already demonstrated estrogen-like
activity of several ginsenosides, including Rg1, Rb1 and
Rh1; however, it remains controversial as to whether or
not the activation of ERa is dependent on ligand binding
[49,52-55]. Nevertheless, the neuroprotective effects of
estrogen also includes nongenomic mechanisms that may
involve MAPK or Akt signaling, as well as its antioxidant
ability, both of which may be ER-independent [56]. Thus,
for the elucidation of the mechanisms of Rh1 and Rg2,
further studies are warranted to test for their possible
interactions with ERa (ligand binding assays; response
genes expression). More investigations on ER-independent
estrogen action may also contribute to our understanding
of ginsenosides’ estrogen-like effects.
Most ginsenosides isolated are present naturally as enan-
tiomeric mixtures [57]. The structural factor involved is
the stereochemistry at carbon-20 position. Recent studies
showed that different stereoisomers of the same ginseno-
side, ie 20(R)-ginsenoside and 20(S)-ginsenoside have dif-
ferent pharmacological effects [58,59]. Conversely, the
present study suggests that the neuroprotective properties
of ginsenosides Rh1 and Rg2 may not be related to their C-
20 stereochemistry. Therefore, whether C-20 stereochem-
istry affects ginsenoside action may vary from case to case.
Further investigation may delineate the structure-function
relationship of ginsenosides.
Conclusion
6-OHDA induces cell death in SH-SY5Y cells in a dose-
dependent manner while pre-incubation with ginsenosides
Figure 6 Comparison of ginsenoside stereoisomers’ effects on
PC-12 cell morphology. The stacked bars illustrate the percentages
of cells that do not possess neurites, possess short neurites only, or
possess long neurites in each treatment group. At least 160 cells
were counted for each treatment. 20(R)-Rh1, 20(S)-Rh1, 20(R)-Rg2 and
20(S)-Rg2 (20 μM) all increased the percentage of cells possessing
short or long neurites in the absence of NGF compared to the
control group. In the presence of NGF (5 ng/ml) the neurite
outgrowth were slightly enhanced, and no obvious difference in the
effects were observed between 20(R)-ginsenosides and 20(S)-
ginsenosides.
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Rh1 and Rg2 may attenuate such toxicity, possibly by anti-
oxidation, activating nuclear receptors or modulations on
intracellular signaling pathways. ERK1/2 phosphorylation
is observed after 6-OHDA treatment in both SH-SY5Y
cells and PC-12 cells. Pre-incubation with Rh1 or Rg2
reduces 6-OHDA-induced ERK1/2 phosphorylation,
which is possibly neuroprotective to the cells. Rh1 and Rg2
also induce neurite outgrowth in wild type PC-12 cells
both in the presence and absence of NGF. C-20 stereo-
chemistry does not play a part in the action of the two gin-
senosides but their exact mechanism of neuroprotection
remains unclear.
Abbreviations
17βE2: 17β-estradiol; 6-OHDA: 6-hydroxydopamine; JNK: c-jun N-terminal
kinase; DA: Dopamine; DMEM/F12: Dulbecco’s modified eagle medium
containing nutrient mixture F-12; ERs: Estrogen receptors; ERKs: extracellular
signal-regulated protein kinases; GRs: glucocorticoid receptors; HS: Horse
Serum; MAPKs: Mitogen-activated protein kinases; NGF: nerve growth factor;
PD: Parkinson’s disease; PSN: Penicillin-Streptomycin-Neomycin; PPD:
protopanaxadiol; PPT: protopanaxatriol; SD: Standard deviation; TR: thyroid
hormone receptor;
Acknowledgements
This study was supported by Hong Kong Baptist University Research
Committee Mini-Area of Excellence Scheme RC/AOE/08-09/02 (to KKLY).
Author details
1Department of Biology, Faculty of Science, Hong Kong Baptist University,
Kowloon Tong, Hong Kong SAR, China. 2School of Chinese Medicine, Hong
Kong Baptist University, Kowloon Tong, Hong Kong SAR, China.
Authors’ contributions
XFL and KKLY designed the study. XFL conducted the experiments, analyzed
the data and drafted the manuscript. CNPL revised the manuscript. ZHJ
helped conduct the experiments. All authors read and approved the final
version of the manuscript.
Competing interests
The authors declare that they have no competing interests.
Received: 14 December 2010 Accepted: 19 May 2011
Published: 19 May 2011
References
1. TT Warner, AH Schapira, Genetic and environmental factors in the cause of
Parkinson’s disease. Ann Neurol. 53(Suppl 3):16–25 (2003)
2. CA Davie, A review of Parkinson’s disease. Br Med Bull. 86, 109–127 (2008).
doi:10.1093/bmb/ldn013
3. K Hanrott, L Gudmunsen, MJ O’Neill, S Wonnacott, 6-Hydroxydopamine-
induced apoptosis is mediated via extracellular auto-oxidation and caspase 3-
dependent activation of protein kinase Cδ. J Biol Chem. 281, 5373–5382 (2006)
4. W Linert, E Herlinger, RF Jameson, E Kienzl, K Jellinger, MB Youdim,
Dopamine, 6-hydroxydopamine, iron, and dioxygen–their mutual
interactions and possible implication in the development of Parkinson’s
disease. Biochim Biophys Acta. 1316, 160–168 (1996)
5. A Napolitano, O Crescenzi, A Pezzella, G Prota, Generation of the
neurotoxin 6-hydroxydopamine by peroxidase/H2O2 oxidation of
dopamine. J Med Chem. 38, 917–922 (1995). doi:10.1021/jm00006a010
6. R Soto-Otero, E Méndez-Alvarez, A Hermida-Ameijeiras, AM Muñoz-Patiño, JL
Labandeira-Garcia, Autoxidation and neurotoxicity of 6-hydroxydopamine in
the presence of some antioxidants: potential implication in relation to the
pathogenesis of Parkinson’s disease. J Neurochem. 74, 1605–1612 (2000)
7. D Blum, S Torch, MF Nissou, AL Benabid, JM Verna, Extracellular toxicity of
6-hydroxydopamine on PC12 cells. Neurosci Lett. 283, 193–196 (2000).
doi:10.1016/S0304-3940(00)00948-4
8. KL Ge, WF Chen, JX Xie, MS Wong, Ginsenoside Rg1 protects against 6-
OHDA-induced toxicity in MES23.5 cells via Akt and ERK signaling pathways.
J Ethnopharmacol. 127, 118–123 (2010). doi:10.1016/j.jep.2009.09.038
9. Z Li, Y Hu, Q Zhu, J Zhu, Neurotrophin-3 reduces apoptosis induced by 6-
OHDA in PC12 cells through Akt signaling pathway. Int J Dev Neurosci. 26,
635–640 (2008). doi:10.1016/j.ijdevneu.2008.03.009
10. J Rodriguez-Blanco, V Martín, F Herrera, G García-Santos, I Antolín, C
Rodriguez, Intracellular signaling pathways involved in post-mitotic
dopaminergic PC12 cell death induced by 6-hydroxydopamine. J
Neurochem. 107, 127–140 (2008). doi:10.1111/j.1471-4159.2008.05588.x
11. WD Rausch, S Liu, G Gille, K Radad, Neuroprotective effects of ginsenosides.
Acta Neurobiol Exp (Wars). 66, 369–375 (2006)
12. H Hasegawa, Proof of the mysterious efficacy of ginseng: basic and clinical
trials: metabolic activation of ginsenoside: deglycosylation by intestinal
bacteria and esterification with fatty acid. J Pharmacol Sci. 95, 153–157
(2004). doi:10.1254/jphs.FMJ04001X4
13. CF Chen, WF Chiou, JT Zhang, Comparison of the pharmacological effects
of Panax ginseng and Panax quinquefolium. Acta Pharmacol Sin. 29,
1103–1108 (2008). doi:10.1111/j.1745-7254.2008.00868.x
14. M Rudakewich, F Ba, CG Benishin, Neurotrophic and neuroprotective
actions of ginsenosides Rb(1) and Rg(1). Planta Med. 67, 533–537 (2001).
doi:10.1055/s-2001-16488
15. XC Chen, F Fang, YG Zhu, LM Chen, YC Zhou, Y Chen, Protective effect of
ginsenoside Rg1 on MPP+-induced apoptosis in SHSY5Y cells. J Neural
Transm. 110, 835–845 (2003). doi:10.1007/s00702-003-0005-y
16. XC Chen, YC Zhou, Y Chen, YG Zhu, F Fang, LM Chen, Ginsenoside Rg1
reduces MPTP-induced substantia nigra neuron loss by suppressing
oxidative stress. Acta Pharmacol Sin. 26, 56–62 (2005). doi:10.1111/j.1745-
7254.2005.00019.x
17. YP Hwang, HG Jeong, Ginsenoside Rb1 protects against 6-
hydroxydopamine-induced oxidative stress by increasing heme oxygenase-
1 expression through an estrogen receptor-related PI3K/Akt/Nrf2-dependent
pathway in human dopaminergic cells. Toxicol Appl Pharmacol. 242, 18–28
(2010). doi:10.1016/j.taap.2009.09.009
18. K Radad, G Gille, R Moldzio, H Saito, K Ishige, WD Rausch, Ginsenosides Rb1
and Rg1 effects on survival and neurite growth of MPP+-affected
mesencephalic dopaminergic cells. J Neural Transm. 111, 37–45 (2004).
doi:10.1007/s00702-003-0063-1
19. K Radad, G Gille, R Moldzio, H Saito, WD Rausch, Ginsenosides Rb1 and Rg1
effects on mesencephalic dopaminergic cells stressed with glutamate. Brain
Res. 1021, 41–53 (2004). doi:10.1016/j.brainres.2004.06.030
20. L Xu, WF Chen, MS Wong, Ginsenoside Rg1 protects dopaminergic neurons
in a rat model of Parkinson’s disease through the IGF-I receptor signalling
pathway. Br J Pharmacol. 158, 738–748 (2009). doi:10.1111/j.1476-
5381.2009.00361.x
21. K Zou, S Zhu, MR Meselhy, C Tohda, S Cai, K Komatsu, Dammarane-type
Saponins from Panax japonicus and their neurite outgrowth activity in SK-
N-SH cells. J Nat Prod. 65, 1288–1292 (2002). doi:10.1021/np0201117
22. LP Christensen, Ginsenosides chemistry, biosynthesis, analysis, and potential
health effects. Adv Food Nutr Res. 55, 1–99 (2008)
23. P Tansakul, M Shibuya, T Kushiro, Y Ebizuka, Dammarenediol-II synthase, the
first dedicated enzyme for ginsenoside biosynthesis, in Panax ginseng. FEBS
Lett. 580, 5143–5149 (2006). doi:10.1016/j.febslet.2006.08.044
24. Wild Rose College and Wholistic Clinic. http://www.wrc.net/
wrcnet_content/herbalresources/materiamedica/materiamedica.aspx?
mmid=15
25. NJ McKenna, RB Lanz, BW O’Malley, Nuclear receptor coregulators: cellular
and molecular biology. Endocr Rev. 20, 321–344 (1999). doi:10.1210/
er.20.3.321
26. BS Katzenellenbogen, I Choi, R Delage-Mourroux, TR Ediger, PG Martini, M
Montano, J Sun, K Weis, JA Katzenellenbogen, Molecular mechanisms of
estrogen action: selective ligands and receptor pharmacology. J Steroid
Biochem Mol Biol. 74, 279–285 (2000). doi:10.1016/S0960-0760(00)00104-7
27. CD Toran-Allerand, Minireview: A plethora of estrogen receptors in the
brain: where will it end? Endocrinology. 145, 1069–1074 (2004)
28. DB Dubal, H Zhu, J Yu, SW Rau, PJ Shughrue, I Merchenthaler, MS Kindy,
PM Wise, Estrogen receptor alpha, not beta, is a critical link in estradiol-
mediated protection against brain injury. Proc Natl Acad Sci USA. 98,
1952–1957 (2001). doi:10.1073/pnas.041483198
29. Y Mérot, F Ferrière, E Debroas, G Flouriot, D Duval, C Saligaut, Estrogen
receptor alpha mediates neuronal differentiation and neuroprotection in
Li et al. Chinese Medicine 2011, 6:19
http://www.cmjournal.org/content/6/1/19
Page 8 of 9
PC12 cells: critical role of the A/B domain of the receptor. J Mol Endocrinol.
35, 257–267 (2005). doi:10.1677/jme.1.01826
30. Y Mérot, F Ferrière, L Gailhouste, G Huet, F Percevault, C Saligaut, G Flouriot,
Different outcomes of unliganded and liganded estrogen receptor-alpha on
neurite outgrowth in PC12 cells. Endocrinology. 150, 200–211 (2009)
31. L Gollapudi, MM Oblinger, Stable transfection of PC12 cells with estrogen
receptor (ERalpha): protective effects of estrogen on cell survival after
serum deprivation. J Neurosci Res. 56, 99–108 (1999). doi:10.1002/(SICI)1097-
4547(19990401)56:13.0.CO;2-G
32. AL Mize, RA Shapiro, DM Dorsa, Estrogen receptor-mediated
neuroprotection from oxidative stress requires activation of the mitogen-
activated protein kinase pathway. Endocrinology. 144, 306–312 (2003).
doi:10.1210/en.2002-220698
33. M Raman, W Chen, MH Cobb, Differential regulation and properties of
MAPKs. Oncogene. 26, 3100–3112 (2007). doi:10.1038/sj.onc.1210392
34. Y Zhang, C Dong, Regulatory mechanisms of mitogen-activated kinase
signaling. Cell Mol Life Sci. 64, 2771–2789 (2007). doi:10.1007/s00018-007-
7012-3
35. YZ Wang, JC Bonner, Mechanism of extracellular signal-regulated kinase
(ERK)-1 and ERK-2 activation by vanadium pentoxide in rat pulmonary
myofibroblasts. Am J Respir Cell Mol Biol. 22, 590–596 (2000)
36. X Wang, JL Martindale, Y Liu, NJ Holbrook, The cellular response to
oxidative stress: influences of mitogen-activated protein kinase signalling
pathways on cell survival. Biochem J. 333, 291–300 (1998)
37. Z Xia, M Dickens, J Raingeaud, RJ Davis, ME Greenberg, Opposing effects of
ERK and JNK-p38 MAP kinases on apoptosis. Science. 270, 1326–1331
(1995). doi:10.1126/science.270.5240.1326
38. M Stanciu, Y Wang, R Kentor, N Burke, S Watkins, G Kress, I Reynolds, E
Klann, MR Angiolieri, JW Johnson, DB DeFranco, Persistent activation of ERK
contributes to glutamate-induced oxidative toxicity in a neuronal cell line
and primary cortical neuron cultures. J Biol Chem. 275, 12200–12206 (2000).
doi:10.1074/jbc.275.16.12200
39. S Subramaniam, U Zirrgiebel, von Bohlen, J Strelau, C Laliberté, DR Kaplan,
K Unsicker, ERK activation promotes neuronal degeneration predominantly
through plasma membrane damage and independently of caspase-3. J Cell
Biol. 165, 357–369 (2004). doi:10.1083/jcb.200403028
40. K Lu, CL Liang, PC Liliang, CH Yang, CL Cho, HC Weng, YD Tsai, KW Wang,
HJ Chen, Inhibition of extracellular signal-regulated kinases (ERK)1/2
provides neuroprotection in spinal cord ischemia/reperfusion injury in rats:
relationship with the nuclear factor-κB-regulated antiapoptotic mechanisms.
J Neurochem. 114, 237–246 (2010)
41. T Satoh, D Nakatsuka, Y Watanabe, I Nagata, H Kikuchi, S Namura,
Neuroprotection by MAPK/ERK kinase inhibition with U0126 against
oxidative stress in a mouse neuronal cell line and rat primary cultured
cortical neurons. Neurosci Lett. 288, 163–166 (2000). doi:10.1016/S0304-3940
(00)01229-5
42. X Wang, H Wang, L Xu, DJ Rozanski, T Sugawara, PH Chan, JM Trzaskos, GZ
Feuerstein, Significant neuroprotection against ischemic brain injury by
inhibition of the MEK1 protein kinase in mice: exploration of potential
mechanism associated with apoptosis. J Pharmacol Exp Ther. 304, 172–178
(2003). doi:10.1124/jpet.102.040246
43. RH Lustig, P Hua, W Yu, FJ Ahmad, PW Baas, An in vitro model for the
effects of estrogen on neurons employing estrogen receptor-transfected
PC12 cells. J Neurosci. 14, 3945–3957 (1994)
44. B Ossola, TM Kääräinen, A Raasmaja, PT Männistö, Time-dependent
protective and harmful effects of quercetin on 6-OHDA-induced toxicity in
neuronal SH-SY5Y cells. Toxicology. 250, 1–8 (2008). doi:10.1016/j.
tox.2008.04.001
45. C Behl, T Skutella, F Lezoualc’h, A Post, M Widmann, CJ Newton, F Holsboer,
Neuroprotection against oxidative stress by estrogens: structure-activity
relationship. Mol Pharmacol. 51, 535–541 (1997)
46. N Li, B Liu, DE Dluzen, Y Jin, Protective effects of ginsenoside Rg2 against
glutamate-induced neurotoxicity in PC12 cells. J Ethnopharmacol. 111,
458–463 (2007). doi:10.1016/j.jep.2006.12.015
47. ZQ Liu, XY Luo, GZ Liu, YP Chen, ZC Wang, YX Sun, In vitro study of the
relationship between the structure of ginsenoside and its antioxidative or
prooxidative activity in free radical induced hemolysis of human
erythrocytes. J Agric Food Chem. 51, 2555–2558 (2003). doi:10.1021/
jf026228i
48. K Samukawa, Y Suzuki, N Ohkubo, M Aoto, M Sakanaka, N Mitsuda,
Protective effect of ginsenosides Rg(2) and Rh(1) on oxidation-induced
impairment of erythrocyte membrane properties. Biorheology. 45, 689–700
(2008)
49. Y Lee, Y Jin, W Lim, S Ji, S Choi, S Jang, S Lee, A ginsenoside-Rh1, a
component of ginseng saponin, activates estrogen receptor in human
breast carcinoma MCF-7 cells. J Steroid Biochem Mol Biol. 84, 463–468
(2003). doi:10.1016/S0960-0760(03)00067-0
50. SM Kulich, C Horbinski, M Patel, CT Chu, 6-Hydroxydopamine induces
mitochondrial ERK activation. Free Radic Biol Med. 43, 372–383 (2007).
doi:10.1016/j.freeradbiomed.2007.04.028
51. E Lin, JE Cavanaugh, RK Leak, RG Perez, MJ Zigmond, Rapid activation of
ERK by 6-hydroxydopamine promotes survival of dopaminergic cells. J
Neurosci Res. 86, 108–117 (2008). doi:10.1002/jnr.21478
52. RY Chan, WF Chen, A Dong, D Guo, MS Wong, Estrogen-like activity of
ginsenoside Rg1 derived from Panax notoginseng. J Clin Endocrinol Metab.
87, 3691–3695 (2002). doi:10.1210/jc.87.8.3691
53. J Cho, W Park, S Lee, W Ahn, Y Lee, Ginsenoside-Rb1 from Panax ginseng
C.A. Meyer activates estrogen receptor-alpha and -beta, independent of
ligand binding. J Clin Endocrinol Metab. 89, 3510–3515 (2004). doi:10.1210/
jc.2003-031823
54. WS Lau, RY Chan, DA Guo, MS Wong, Ginsenoside Rg1 exerts estrogen-like
activities via ligand-independent activation of ERalpha pathway. J Steroid
Biochem Mol Biol. 108, 64–71 (2008). doi:10.1016/j.jsbmb.2007.06.005
55. YJ Lee, YR Jin, WC Lim, WK Park, JY Cho, S Jang, SK Lee, Ginsenoside-Rb1
acts as a weak phytoestrogen in MCF-7 human breast cancer cells. Arch
Pharm Res. 26, 58–63 (2003). doi:10.1007/BF03179933
56. KM Dhandapani, DW Brann, Protective effects of estrogen and selective
estrogen receptor modulators in the brain. Biol Reprod. 67, 1379–1385
(2002). doi:10.1095/biolreprod.102.003848
57. F Soldati, O Sticher, HPLC separation and quantitative determination of
ginsenosides from Panax ginseng, Panax quinquefolium and from ginseng
drug preparations. 2nd communication. Planta Med. 39, 348–357 (1980).
doi:10.1055/s-2008-1074929
58. DI Kang, JY Lee, JY Yang, SM Jeong, JH Lee, SY Nah, Y Kim, Evidence that
the tertiary structure of 20(S)-ginsenoside Rg(3) with tight hydrophobic
packing near the chiral center is important for Na(+) channel regulation.
Biochem Biophys Res Commun. 333, 1194–1201 (2005). doi:10.1016/j.
bbrc.2005.06.026
59. J Liu, J Shiono, K Shimizu, H Yu, C Zhang, F Jin, R Kondo, 20(R)-ginsenoside
Rh2, not 20(S), is a selective osteoclastgenesis inhibitor without any
cytotoxicity. Bioorg Med Chem Lett. 19, 3320–3323 (2009). doi:10.1016/j.
bmcl.2009.04.054
doi:10.1186/1749-8546-6-19
Cite this article as: Li et al.: Neuroprotective effects of ginsenosides Rh1
and Rg2 on neuronal cells. Chinese Medicine 2011 6:19.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Li et al. Chinese Medicine 2011, 6:19
http://www.cmjournal.org/content/6/1/19
Page 9 of 9
